Enzolytics announced its ongoing efforts to develop fully feline Monoclonal Antibodies. Enzolytics utilizes its proprietary Artificial Intelligence (AI) platform to produce species-specific monoclonal antibodies. Abveris, a Boston-based biotechnology company providing contract research services to biopharmaceutical industry partners, will use feline donor PBMC samples and peptide screening tools provided by Enzolytics to perform a B cell screening-based Ab discovery project to identify antigen-binding antibodies for further characterization by Enzolytics.

The resulting fully feline monoclonal antibodies are expected to be used in scientific applications, including ELISA, Western Blot, immunohistochemistry, and immunocytochemistry for diagnostics. There are more than 150 million cats in the U.S. and over 25% of households in America own cats. Production of monoclonal antibodies targeting feline viruses may be more direct and the time to market will be significantly less than is the case required for monoclonal antibodies developed for the treatment of humans.

Enzolytics has initiated discussions with animal health providers who express an interest in this technology.